Beardsley Robert A 4

What Happened
Robert A. Beardsley, a director of Arbutus Biopharma Corp (ABUS), was granted a derivative award covering 78,800 shares on June 8, 2026. The Form 4 reports the acquisition price as $0.00 (transaction code A — grant/award). A footnote in the filing indicates the instrument is an option that is fully vested and exercisable as of the grant date.

Key Details

• Transaction date: 2026-06-08; Form 4 filed: 2026-06-10 (timely filing).
• Security: derivative (option) covering 78,800 shares; reported acquisition price $0.00.
• Footnote F1: filing references the company’s Nasdaq closing price on the grant date (value not shown here).
• Footnote F2: the option is fully vested and exercisable as of the grant date.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context
This was an award/option grant (not an open‑market purchase or sale). Because the option is fully vested and exercisable immediately, Beardsley could exercise the option per its terms, but the Form 4 shows no immediate sale. Awards to directors are commonly part of compensation or retention programs and are not by themselves a definitive signal of personal buying or selling intent.